Non-Obstructive Azoospermia (NOA)

Causes, Genetic Factors, Diagnosis, Micro-TESE, ICSI, Treatment Options and an Integrative Unani Approach

By Dr. Nizamuddin Qasmi
Founder & Chief Physician, Saira Health Care
Focused Practice in Sexual Disorders & Infertility

BUMS – Hamdard University, Delhi
MD, CGO
Certificate in Infertility – MGBIMS, Delhi
Certificate in Urology – London, UK
Masters in Male Infertility – MasterHealthPro (HealthPro)
Integrated Sexual and Reproductive Health – ISRH, UNFPA

Medical and reproductive-health literature reviewed and updated through September 2026.

Introduction

When a man receives a semen report stating “azoospermia – no sperm seen,” it is understandable that he may feel frightened.

One of the first questions patients ask me is:

“Doctor, does this mean my body has completely stopped producing sperm?”

My answer is:

Not necessarily—but we must determine exactly why sperm are absent from the semen.

Azoospermia has two major biological patterns.

In obstructive azoospermia, sperm may be produced normally or relatively normally inside the testes, but a blockage prevents them from entering the ejaculate.

In non-obstructive azoospermia (NOA), the main problem is different. Sperm production itself is absent or severely impaired, or the hormonal stimulation required for spermatogenesis is inadequate.

Azoospermia affects approximately 1% of the male population and around 10–15% of infertile men. Non-obstructive causes account for the majority of azoospermia cases.

NOA is therefore one of the most serious forms of male-factor infertility. But serious does not mean hopeless.

Modern reproductive medicine has changed the outlook substantially. Some men with NOA have tiny, isolated areas within the testis where sperm production is still occurring. Those rare sperm may sometimes be located through microdissection testicular sperm extraction (micro-TESE) and used for intracytoplasmic sperm injection (ICSI).

Current European guidance recognizes micro-TESE as the preferred sperm-retrieval approach for appropriately selected men with NOA, while also emphasizing that no routine blood test, hormone level or testicular measurement can guarantee whether sperm will be found.

This is why I believe every patient with NOA deserves a systematic evaluation before conclusions are made.

What Is Non-Obstructive Azoospermia?

Non-obstructive azoospermia means that no sperm are detected in the ejaculated semen because sperm production is absent or severely impaired rather than because of a mechanical blockage in the reproductive ducts.

In simple language:

The problem is mainly in sperm production rather than sperm transport.

However, this definition includes several very different biological situations.

One man may have severe primary testicular failure.

Another may have Klinefelter syndrome.

Another may carry a Y-chromosome microdeletion.

Another may have a history of bilateral undescended testes.

Another may have lost sperm production after chemotherapy.

And another may have inadequate hormonal stimulation from the pituitary gland—a very different and sometimes medically treatable situation.

This is why I do not regard “NOA” as the final explanation.

It is a diagnostic category that tells us where the problem probably lies. We must still investigate the underlying cause.

Non-Obstructive Azoospermia Versus Obstructive Azoospermia

This distinction determines treatment.

Current EAU guidance notes that men with primary testicular deficiency typically show hypergonadotropic hypogonadism, meaning elevated FSH and LH, sometimes accompanied by low testosterone. But normal FSH does not exclude NOA, particularly in conditions such as maturation arrest.

Therefore, no single laboratory value should be used alone to decide whether a patient has obstruction or failure of spermatogenesis.

Azoospermia Must First Be Confirmed Properly

This is a very important step.

A patient should not be permanently labelled with NOA simply because one laboratory report says “zero sperm.”

Current EAU guidance recommends confirming NOA on two consecutive semen analyses, with no sperm found after appropriate centrifugation of the semen sample.

Why does centrifugation matter?

Occasionally, sperm numbers are so extremely low that none are seen in a routine drop of semen. After concentrating the sample and carefully examining the sediment, a few sperm may be discovered.

That condition is cryptozoospermia, not absolute azoospermia.

This difference can change fertility treatment dramatically.

Before discussing surgery, I therefore want to know:

Was the full sample collected?

Was the semen processed correctly?

Was the concentrated pellet examined carefully?

Was testing repeated?

Were rare sperm ever seen previously?

Good infertility treatment begins with a correct laboratory diagnosis.

Does NOA Mean the Testes Produce Absolutely No Sperm?

Not always.

This is one of the most important facts for patients to understand.

Spermatogenesis in NOA can be patchy or focal.

Large areas of testicular tissue may contain no mature sperm, while a small isolated seminiferous tubule may still complete spermatogenesis.

The EAU describes this focal pattern and reports sperm-retrieval rates approaching approximately 50% in many NOA series, although results vary substantially between populations, causes and surgical techniques.

A 2026 review similarly places typical micro-TESE sperm-retrieval rates in the broad range of approximately 40–60%, emphasizing major variation according to genetics, histology, endocrine phenotype and surgical expertise.

This does not mean every NOA patient has a 50% personal chance.

Population averages cannot predict an individual patient's result with certainty.

How Normal Sperm Production Works

Sperm production takes place inside microscopic structures in the testes called seminiferous tubules.

The process requires several cell types and hormones.

The hypothalamus in the brain releases GnRH.

GnRH stimulates the pituitary gland to release:

• FSH
• LH

LH stimulates Leydig cells in the testis to produce testosterone.

FSH acts particularly on Sertoli-cell functions that support developing germ cells.

Within the seminiferous tubules, primitive germ cells gradually develop through several stages until mature spermatozoa are produced.

A defect at any major step can interrupt spermatogenesis.

Therefore, NOA can result from:

• Failure of hormonal stimulation
• Loss of germ cells
• Failure of germ cells to mature
• Chromosomal abnormalities
• Gene mutations
• Testicular injury
• Toxic exposure
• Developmental disorders
• Or causes that remain unexplained

Major Histological Patterns in NOA

When testicular tissue is examined during an indicated sperm-retrieval procedure, several patterns may be identified.

These are useful concepts for understanding why NOA behaves differently between patients.

Hypospermatogenesis

In hypospermatogenesis, all stages of sperm development are present, but sperm production is greatly reduced.

Of the common NOA histological patterns, this generally has the most favorable association with sperm retrieval.

The EAU notes that hypospermatogenesis is associated with a better chance of retrieving sperm than maturation arrest or Sertoli-cell-only patterns.

Maturation Arrest

In maturation arrest, germ cells begin developing but stop at a particular stage before mature sperm are formed.

Early maturation arrest generally carries a poorer prognosis than later-stage arrest.

One important diagnostic point is that FSH may remain normal in some men with maturation arrest because early germ cells may still be present.

Therefore:

normal FSH does not prove that sperm production is normal.

Sertoli-Cell-Only Syndrome

In Sertoli-cell-only syndrome (SCOS), seminiferous tubules contain Sertoli cells but lack germ cells in the examined area.

It is sometimes called germ-cell aplasia.

A 2025 review describes SCOS as one of the most frequent histological findings in men with NOA and notes that it may arise from genetic abnormalities, toxic exposures, infections, radiation or unidentified causes.

Importantly, finding SCOS in one biopsy does not always mean every part of the testis is identical.

Some men can still have isolated areas of sperm production elsewhere.

That is one reason routine diagnostic biopsy before definitive sperm retrieval is generally discouraged. The EAU recommends against a separate diagnostic biopsy before TESE because even severely abnormal testes can contain focal spermatogenesis.

What Causes Non-Obstructive Azoospermia?

There are many causes.

For practical understanding, I divide them into several major groups.

1. Genetic Causes

Genetic abnormalities are particularly important in NOA.

The more severe the impairment of sperm production, the greater the probability of detecting an important genetic cause.

Current EAU guidance recommends standard karyotype analysis and genetic counselling for men with azoospermia and Y-chromosome microdeletion testing in the severe sperm-deficiency range.

For a man with confirmed NOA, these tests are not simply academic.

They can influence:

• Diagnosis
• General-health counselling
• Whether micro-TESE is reasonable
• Expected sperm-retrieval probability
• Risk to future children
• Decisions about assisted reproduction

Klinefelter Syndrome

Klinefelter syndrome, usually 47,XXY, is one of the most important chromosomal conditions associated with severe male infertility.

Men may have:

• Small, firm testes
• Elevated FSH and LH
• Low or borderline testosterone
• Azoospermia
• Reduced fertility

Some men have few other obvious physical features and are diagnosed only during an infertility evaluation.

The EAU notes that sperm may still be retrieved with TESE/micro-TESE in a meaningful proportion of azoospermic men with Klinefelter syndrome.

A 2025 systematic review and meta-analysis of 2,815 men with non-mosaic Klinefelter syndrome reported a median surgical sperm-retrieval rate of approximately 44%, with no compelling evidence that routine retrieval during adolescence is superior to appropriately timed retrieval in adulthood.

This is important because patients should neither be told that sperm retrieval is impossible nor promised that it will succeed.

Klinefelter Syndrome Is Also a General-Health Diagnosis

Klinefelter syndrome has implications beyond fertility.

Current EAU guidance notes increased risks of metabolic and cardiovascular disorders and recommends appropriate long-term medical follow-up.

Therefore, discovering a genetic cause during infertility evaluation can sometimes improve the patient's broader healthcare as well.

Y-Chromosome Microdeletions

The Y chromosome contains regions important for sperm production known collectively as the AZF regions:

• AZFa
• AZFb
• AZFc

Y-chromosome microdeletions are found much more frequently in men with severe impairment of spermatogenesis.

EAU data estimate Y-chromosome microdeletions in approximately 8–12% of men with non-obstructive azoospermia.

But the exact region deleted is critically important.

AZFa Deletion

Complete AZFa deletion is strongly associated with a severe Sertoli-cell-only phenotype.

Current guidelines consider successful sperm retrieval essentially absent with complete AZFa deletion.

AZFb Deletion

Complete AZFb deletion is typically associated with profound spermatogenic arrest.

Again, the probability of mature sperm retrieval is essentially negligible.

The EAU therefore strongly recommends not performing surgical sperm retrieval when complete AZFa or AZFb deletions are present.

This is an excellent example of how genetic testing can prevent an unnecessary operation.

AZFc Deletion

AZFc deletion has a much more variable phenotype.

Some men are azoospermic.

Others have severe oligozoospermia.

And in azoospermic men, testicular sperm may still be found in a significant proportion.

The EAU reports sperm retrieval in roughly 50–75% of men with AZFc microdeletions in published series.

However, an important reproductive issue exists:

A son conceived using sperm carrying an AZFc deletion will inherit the Y-chromosome deletion.

Genetic counselling before ICSI is therefore essential.

Newer Genetic Testing

The genetic understanding of NOA is expanding rapidly.

Traditional routine evaluation focuses primarily on karyotype and Y-chromosome microdeletion testing.

However, next-generation sequencing is identifying an increasing number of single-gene causes of impaired spermatogenesis.

A large multicentre study published in 2025 evaluating a NOA-specific gene panel reported a diagnostic yield of about 6.1% and identified genetic variants associated with different sperm-retrieval outcomes.

A 2025 review also describes emerging genes involved in meiosis, DNA repair and germ-cell development.

These developments are promising, but expanded genetic panels are not yet a universally standardized replacement for conventional genetic testing.

Interpretation should ideally involve genetics expertise because some variants remain of uncertain significance.

2. Undescended Testes – Cryptorchidism

A history of one or both testes failing to descend normally during childhood can affect future sperm production.

The effect is generally more severe when:

• Both testes were undescended
• Correction occurred late
• The testes were located higher in the abdomen
• Significant testicular damage developed

Men with previous cryptorchidism can later present with severe oligozoospermia or NOA.

Current evidence indicates that sperm can still sometimes be retrieved surgically in men with NOA following previous orchiopexy. A 2025 systematic review and meta-analysis specifically examined sperm-retrieval and ICSI outcomes in this population.

A history of childhood testicular surgery is therefore important even decades later.

3. Testicular Torsion or Trauma

Testicular torsion cuts off blood flow to the testis.

If severe or prolonged, permanent testicular damage can occur.

Major bilateral trauma can likewise affect sperm-producing tissue.

The impact depends on how much functional testicular tissue remains.

4. Mumps Orchitis and Other Testicular Infections

Post-pubertal mumps can occasionally cause significant inflammation of the testes.

When both testes are severely involved, spermatogenesis may become permanently impaired.

Other significant infections and inflammatory conditions can also damage testicular tissue.

These causes are recognized among established acquired etiologies of NOA.

5. Chemotherapy and Radiotherapy

Cancer treatment can save life but may injure rapidly dividing germ cells.

The risk depends upon:

• Chemotherapy agent
• Dose
• Combination of medicines
• Radiation field
• Radiation dose
• Patient age
• Baseline testicular function

Some men recover sperm production after treatment.

Others develop permanent NOA.

For this reason, sperm cryopreservation before gonadotoxic cancer treatment is extremely important whenever possible.

A man should ideally discuss fertility preservation before treatment rather than after azoospermia has developed.

6. Testosterone and Anabolic Steroids

This is one of the most preventable causes of severe sperm suppression.

Many men mistakenly think:

“Testosterone is the male hormone, so taking testosterone should increase sperm.”

The opposite may occur.

Exogenous testosterone suppresses pituitary LH and FSH.

That lowers intratesticular testosterone—the very high local testosterone concentration required for spermatogenesis.

As a result, sperm counts can become extremely low or reach azoospermia.

Current EAU guidelines state clearly:

Testosterone should not be used as treatment for male infertility.

Men using anabolic steroids for bodybuilding may develop a similar problem.

EAU guidance recommends withdrawing anabolic steroids in infertile men, allowing an appropriate recovery interval before considering additional fertility-directed hormonal therapy.

7. Hormonal Failure – Hypogonadotropic Hypogonadism

Not every NOA patient has damaged testes.

Some men have inadequate hormonal stimulation from the hypothalamus or pituitary.

This is called hypogonadotropic hypogonadism.

The testes may retain significant capacity to produce sperm, but they are not receiving enough FSH and LH stimulation.

This is one of the most important exceptions because it can be medically treatable.

Depending on the cause, treatment with hCG and FSH or related gonadotropin therapy can induce spermatogenesis.

EAU guidelines strongly recommend effective gonadotropin-based therapy to induce sperm production in men with congenital or acquired hypogonadotropic hypogonadism who desire fertility.

Therefore, a man with azoospermia and low gonadotropins should not automatically proceed directly to micro-TESE.

The endocrine cause must be addressed first.

8. Hyperprolactinemia and Pituitary Disease

Excess prolactin can suppress GnRH and reduce LH and FSH.

This may lead to:

• Low testosterone
• Reduced libido
• Erectile dysfunction
• Reduced sperm production

When hyperprolactinemia is confirmed, the underlying cause should be investigated.

EAU guidance supports dopamine-agonist treatment in appropriately selected men with proven hyperprolactinemia.

This represents another potentially reversible endocrine cause.

9. Varicocele

Varicocele is an enlargement of veins around the testis and can be associated with impaired testicular function.

Its role in established NOA is controversial.

AUA/ASRM guidance specifically advises couples with clinical varicocele plus NOA that definitive evidence supporting varicocele repair before surgical sperm retrieval is lacking.

Some newer observational studies and 2026 reviews suggest that carefully selected men may benefit, but this remains a much weaker evidence base than varicocele repair in men who still have sperm in the ejaculate.

Therefore, I would not recommend varicocele surgery automatically to every azoospermic man.

Important considerations include:

• Whether the varicocele is clinically palpable
• Testicular condition
• Hormonal profile
• Female partner's age
• Ovarian reserve
• Time available before ART
• Previous sperm-retrieval history

10. Idiopathic Non-Obstructive Azoospermia

In some patients, no definitive cause is identified despite appropriate testing.

This is called idiopathic NOA.

As genetics and molecular diagnostics improve, some cases currently labelled idiopathic will probably receive more precise diagnoses.

Research is now examining genomic, transcriptomic, proteomic and other biomarkers to identify previously hidden causes and perhaps predict sperm retrieval more accurately.

But these technologies remain largely developmental.

Symptoms of Non-Obstructive Azoospermia

NOA often causes no obvious physical symptoms.

A patient may have:

• Normal erections
• Normal ejaculation
• Normal orgasm
• Normal libido
• Normal-looking semen

and still have no sperm in the ejaculate.

This is why many men discover NOA only when pregnancy does not occur.

Depending on the underlying cause, some may also have:

• Small testes
• Reduced facial or body hair
• Reduced libido
• Erectile problems
• Gynecomastia
• Symptoms of low testosterone
• Delayed puberty
• History of undescended testes
• Previous chemotherapy
• Genetic or developmental features

But none of these is required.

NOA Does Not Mean Impotence

Azoospermia describes fertility, not sexual performance.

A man with NOA can have:

• A strong erection
• Normal intercourse
• Normal ejaculation
• Normal sexual desire

because sperm production and erectile function involve different biological systems.

I consider this distinction particularly important because many patients experience severe psychological distress after receiving the diagnosis.

A semen report does not measure masculinity.

How I Evaluate a Man With Suspected NOA

A proper evaluation is much more than repeating sperm-count tests.

Current EAU guidelines recommend comprehensive assessment including medical history, hormonal profile, genetic testing and scrotal ultrasound in patients with NOA.

At Saira Health Care, I regard the investigation as an attempt to answer several separate questions:

Is the azoospermia genuine?

Is it obstructive or non-obstructive?

Is there a medically reversible cause?

Is there an important genetic diagnosis?

Is micro-TESE appropriate?

Could the patient transmit a genetic condition?

Does he have low testosterone or another health problem requiring long-term care?

And how much reproductive time does the couple have?

Medical and Reproductive History

Important questions include:

• Has the man previously fathered a pregnancy?
• Was puberty normal?
• Were the testes descended normally?
• Was orchiopexy performed?
• Has he had mumps orchitis?
• Testicular torsion?
• Scrotal trauma?
• Cancer treatment?
• Groin or testicular surgery?
• Testosterone injections?
• Gym steroids?
• Opioids or other relevant medicines?
• Significant environmental or occupational exposure?
• Family history of infertility?
• Family history of genetic disease?

A detailed history can sometimes reveal the cause before advanced investigations begin.

Physical Examination

Examination should include assessment of:

• Testicular size
• Testicular consistency
• Epididymides
• Vas deferens
• Varicocele
• Signs of androgen deficiency
• Secondary sexual characteristics

Small, firm testes combined with high FSH suggest significant primary testicular failure.

However, even small testes and very high FSH do not prove that micro-TESE will fail, because focal spermatogenesis can still occasionally exist.

Hormonal Evaluation

Current European guidance strongly recommends measuring:

FSH, LH and total testosterone in men with azoospermia.

Depending on the clinical picture, additional testing can include:

• Prolactin
• Estradiol
• Thyroid studies
• SHBG
• Repeat morning testosterone

FSH is particularly informative but must be interpreted correctly.

Very high FSH suggests major testicular impairment.

Yet the EAU specifically states that FSH does not accurately predict whether small areas of spermatogenesis are present at micro-TESE.

Therefore:

A high FSH should not automatically be used to tell a patient that sperm retrieval is impossible.

Genetic Evaluation

For confirmed NOA, genetic investigation is one of the most important stages.

The EAU recommends karyotype analysis and genetic counselling for all men with azoospermia.

Y-chromosome microdeletion testing is also strongly indicated in this population.

Genetic testing can:

• Reveal the cause
• Predict when sperm retrieval is futile
• Identify risks to offspring
• Guide ART counselling
• Reveal conditions requiring general medical follow-up

Couples with identified genetic abnormalities should receive genetic counselling before assisted reproduction.

Scrotal Ultrasound

Ultrasound can help assess:

• Testicular volume
• Testicular architecture
• Varicocele
• Unexpected testicular lesions
• Other structural abnormalities

Current EAU guidance includes scrotal ultrasound within comprehensive NOA evaluation and also notes that infertile men have increased testicular-cancer risk compared with the general population.

Ultrasound cannot, however, tell us with certainty whether a few seminiferous tubules contain sperm.

Should a Diagnostic Testicular Biopsy Be Done First?

Usually, no.

A separate biopsy solely to predict whether sperm will later be found is generally discouraged.

The EAU states that testicular biopsy before TESE is not recommended because sperm production may be extremely focal, meaning one biopsy can miss the relevant area.

If testicular tissue is being taken for a medically indicated sperm-retrieval procedure, histology can be assessed at that time.

This avoids subjecting the patient to one invasive operation simply to decide whether another invasive operation should follow.

Can FSH Predict Whether Micro-TESE Will Succeed?

Not reliably enough.

This is a common misunderstanding.

A man may see FSH of 25, 30 or even higher and be told:

“Your FSH is too high; no sperm can possibly be found.”

That conclusion is too strong.

Higher FSH often reflects more severe testicular dysfunction, but it does not prove complete absence of focal spermatogenesis.

A 2024 systematic review and meta-analysis found differences in FSH, inhibin B and AMH between successful and unsuccessful retrieval groups but concluded that none functioned as a sufficiently reliable stand-alone predictor for clinical decision-making.

Current EAU guidance reaches the same practical conclusion: no definitive preoperative predictor of positive sperm retrieval has been established.

Can Testicular Size Predict Success?

Again, not reliably enough for an individual decision.

Larger testicular volume is associated with better retrieval in some studies.

But men with small testes can still have focal sperm production.

The EAU therefore specifically cautions against using preoperative clinical and biochemical variables as sufficiently reliable predictors of micro-TESE outcome.

New 2026 Predictive Research

Research is moving toward combining several variables instead of relying on one laboratory value.

A multicentre study published in July 2026 examined 333 men with idiopathic NOA undergoing micro-TESE. The overall sperm-retrieval rate was 52.55%, and FSH plus histological patterns such as maturation arrest and Sertoli-cell-only syndrome contributed to a predictive nomogram.

This is scientifically promising.

But such models still require external validation and should not be used to promise an individual patient either success or failure.

Similarly, artificial intelligence and molecular markers are under study, but current guidelines still state that dependable prediction before surgery remains an unmet need.

Treatment of Non-Obstructive Azoospermia

There is no single treatment for NOA.

The correct approach depends on the underlying mechanism.

I divide treatment into three broad questions:

Can sperm production be restored medically?

Can a modifiable factor be corrected?

If mature sperm are not entering the ejaculate, can focal testicular sperm be retrieved for ICSI?

Treatable Hormonal NOA

Hypogonadotropic hypogonadism is one of the most important medically treatable causes.

When FSH and LH stimulation is inadequate, gonadotropin therapy may initiate or restore sperm production.

EAU guidance recommends hCG together with FSH-containing therapy according to the endocrine situation for men with congenital or acquired hypogonadotropic hypogonadism seeking fertility.

This process can take months.

Spermatogenesis is biologically slow.

Therefore, patients should not expect a normal semen analysis after a few days or weeks of hormonal therapy.

Primary Testicular Failure Is Different

When the testes are already receiving strong hormonal stimulation—as shown by high FSH—but spermatogenesis remains severely impaired, giving even more hormones does not necessarily correct the underlying cellular problem.

Current EAU guidance states that there is no substantial evidence that gonadotropins, selective estrogen receptor modulators or aromatase inhibitors reliably restore spermatogenesis in classical primary testicular failure.

This is a crucial distinction.

Hormonal medicine can be extremely effective in the right endocrine disease and largely ineffective in the wrong one.

Hormonal Treatment Before Micro-TESE

This has become an area of significant debate.

Some fertility centres prescribe:

• hCG
• FSH
• Clomiphene
• Aromatase inhibitors
• Combinations of these

before micro-TESE.

The biological theory is that optimizing endogenous testosterone and Sertoli/Leydig-cell function may improve focal spermatogenesis.

However, current guidelines remain cautious.

The EAU states that conclusive evidence for routine hormonal stimulation before TESE/micro-TESE in NOA is lacking and advises against routine use outside clinical trials.

A 2026 review of phenotype-guided hormonal optimization similarly concludes that the available evidence remains mostly observational and low certainty; any endocrine pretreatment should therefore be individualized rather than routinely prescribed to all NOA patients.

A second 2026 review also emphasizes phenotype-directed rather than empirical hormonal therapy.

So the current position is not “hormones never work.”

It is:

Hormones should be used when the patient's endocrine physiology provides a rational indication—not as an automatic protocol for every patient with NOA.

Testosterone Must Be Avoided When Fertility Is Desired

This deserves special emphasis.

External testosterone is not fertility treatment.

It can suppress LH, FSH and intratesticular testosterone, reducing or stopping sperm production.

Current EAU guidelines classify testosterone treatment as contraindicated in infertile men seeking conception.

Men should disclose:

• Testosterone injections
• Testosterone gels
• “TRT”
• Anabolic steroids
• Gym hormones

before fertility treatment.

Microdissection Testicular Sperm Extraction – Micro-TESE

For many men with NOA in whom ejaculated sperm cannot be obtained and biological fatherhood is desired, micro-TESE is the principal surgical sperm-retrieval technique.

AUA/ASRM guidelines specifically recommend micro-TESE for men with NOA undergoing surgical sperm retrieval.

The EAU likewise recommends micro-TESE as the treatment of choice for sperm retrieval in NOA, while acknowledging limitations in the comparative evidence base.

How Micro-TESE Works

Micro-TESE is performed through a surgical opening in the testis.

Under an operating microscope, the surgeon examines seminiferous tubules carefully.

Tubules that appear larger or more promising are selectively removed in very small amounts and passed to the embryology laboratory.

The embryologist then searches the tissue intensively for mature sperm.

The fundamental idea is to find small islands of spermatogenesis while removing as little unnecessary testicular tissue as possible.

This is particularly valuable in NOA because sperm production may be highly focal.

How Successful Is Micro-TESE?

There is no single success rate that applies to every patient.

A major review of nearly 4,900 men reported sperm retrieval in approximately 46–47% overall, with published individual study rates ranging widely.

The EAU summarizes positive retrieval rates approaching 50% across heterogeneous NOA populations and notes considerable variability by patient population and technique.

Recent 2026 reviews generally describe a practical range of approximately 40–60%.

I therefore prefer to tell patients:

Micro-TESE offers a realistic possibility of finding sperm in selected NOA patients, but there is no guarantee.

Why Micro-TESE May Be Preferred

Compared with random conventional biopsies, micro-TESE allows the surgeon to target seminiferous tubules that appear more likely to contain sperm.

AUA/ASRM guidance notes evidence suggesting micro-TESE can achieve higher retrieval than non-microsurgical extraction while removing less testicular tissue.

The EAU also reports lower rates of hematoma and fibrosis compared with conventional TESE in available studies.

However, micro-TESE is a specialist operation, and outcomes depend partly on surgical and embryology expertise.

Risks of Micro-TESE

Micro-TESE is generally well tolerated when properly performed, but it is not risk-free.

Potential complications include:

• Pain
• Swelling
• Bleeding
• Hematoma
• Infection
• Fibrosis
• Testicular tissue loss
• Reduced testosterone

A review of micro-TESE literature reported relatively low short-term complication rates but confirmed that temporary or occasionally significant testosterone reductions can occur.

Current EAU evidence indicates testosterone may fall after testicular sperm-extraction procedures and later recover toward baseline in many patients, although individual outcomes differ.

Hormonal follow-up can therefore be appropriate.

Why Micro-TESE Should Not Be Done in Complete AZFa or AZFb Deletion

This is one of the clearest situations in NOA management.

If genetic testing identifies a complete AZFa or complete AZFb deletion, current evidence indicates essentially no realistic sperm-retrieval probability.

Both EAU and AUA/ASRM guidance advise against surgical sperm extraction in these circumstances.

Performing surgery despite this information would expose the patient to cost and risk without a realistic biological benefit.

Klinefelter Syndrome and Micro-TESE

Men with Klinefelter syndrome are different.

Despite severe spermatogenic impairment, focal sperm production can exist.

Current European guidance reports sperm retrieval in up to approximately half of selected azoospermic men with Klinefelter syndrome.

The 2025 meta-analysis cited earlier estimated an overall median retrieval of about 44%.

Therefore, Klinefelter syndrome should not automatically be considered equivalent to complete sterility.

What Happens if Sperm Are Found?

If viable sperm are found, they can generally be used for ICSI.

During ICSI:

1. The female partner undergoes ovarian stimulation.
2. Mature eggs are collected.
3. An embryologist selects an individual viable sperm.
4. The sperm is injected directly into the egg.
5. Resulting embryos are cultured.
6. An embryo may later be transferred to the uterus.

ICSI is necessary because the number of sperm obtained during micro-TESE is generally far too small for conventional insemination.

Finding Sperm Is Not the Same as Achieving Pregnancy

This distinction should be explained carefully.

There are several separate stages:

successful sperm retrieval → successful fertilization → embryo development → implantation → clinical pregnancy → live birth

Success at one stage does not guarantee the next.

Historical meta-analysis summarized by the EAU reported live-birth rates of up to roughly 28% per ICSI cycle in selected NOA series, while results vary substantially according to female age, egg quality, laboratory performance and other factors.

Therefore, a man's micro-TESE result cannot be interpreted independently from the female partner's reproductive health.

Why the Female Partner Must Be Evaluated Before Micro-TESE

I consider this essential.

Suppose micro-TESE finds sperm.

If the female partner has severe diminished ovarian reserve, blocked tubes are irrelevant for IVF but egg yield and age become highly important.

If she is younger with good ovarian reserve, treatment can be planned differently.

WHO's first global infertility guideline, published in November 2025, emphasizes systematic evaluation and person-centred management of both partners rather than treating male and female factors in isolation.

The couple's reproductive plan—not merely the man's sperm-retrieval operation—should therefore be coordinated.

Fresh or Frozen Micro-TESE Sperm?

Both approaches are used.

Some centres coordinate micro-TESE with egg retrieval so fresh sperm can be used immediately.

Other centres retrieve sperm first and freeze it.

AUA/ASRM guidelines allow ICSI with either fresh or cryopreserved surgically retrieved sperm.

In NOA, very small sperm numbers can make freezing more challenging, so the decision depends heavily on laboratory expertise and the individual case.

What if the First Micro-TESE Fails?

Failure of the first micro-TESE is understandably devastating, but it does not always mean another retrieval can never succeed.

A 2024 review of repeat or salvage micro-TESE found sperm-retrieval rates commonly in the range of approximately 10–21% after a previous failed micro-TESE, with some studies reporting higher results.

The EAU also describes variable success in repeat procedures and emphasizes that evidence is heterogeneous.

Histology matters.

Hypospermatogenesis is generally associated with better repeat retrieval than Sertoli-cell-only syndrome or maturation arrest.

But repeat surgery requires careful consideration of:

• Previous operative details
• Histology
• Genetics
• Testicular condition
• Hormones
• Time since surgery
• Couple's remaining reproductive options

It should not be repeated automatically.

Can Varicocele Surgery Help Before Micro-TESE?

This remains controversial.

Some newer studies suggest better sperm-retrieval outcomes after varicocele treatment in selected men with clinical varicocele.

A 2026 review describes promising observational results in selected cohorts.

However, AUA/ASRM guidelines continue to state that there is no definitive evidence supporting routine varicocele repair before ART in men with NOA.

Therefore, the decision should be individualized rather than marketed as a guaranteed way to convert NOA into sperm-producing semen.

Lifestyle Treatment

Lifestyle optimization is important, but expectations need to be realistic.

A healthy lifestyle can support testicular and metabolic health.

Useful measures include:

• Stop smoking
• Avoid anabolic steroids
• Avoid excessive alcohol
• Maintain healthy body weight
• Exercise regularly
• Control diabetes
• Improve sleep
• Avoid unnecessary gonadotoxic exposure
• Maintain adequate nutrition

WHO's 2025 infertility guideline emphasizes healthy diet, physical activity and tobacco cessation as general reproductive-health measures.

However:

Lifestyle cannot remove an AZFa deletion or regenerate absent germ cells in severe Sertoli-cell-only syndrome.

Supportive measures are valuable, but they should not replace appropriate genetic and reproductive investigation.

Antioxidants and Supplements

Oxidative stress is relevant to male reproductive health, but supplement marketing often exceeds the evidence.

In NOA, the biological problem is frequently much deeper than oxidative damage alone.

A man may have chromosomal disease, germ-cell loss or meiotic arrest.

Taking multiple vitamins cannot correct these mechanisms.

For this reason, I prefer supplements only when there is a reasonable clinical indication rather than giving every NOA patient a long list of antioxidants and promising sperm production.

Stem-Cell Treatment for NOA

Patients increasingly see advertisements claiming that stem cells can restore sperm production.

This area is experimental.

A phase-I study has investigated autologous bone-marrow-derived mesenchymal stromal/stem cells in men with NOA, mainly to evaluate feasibility and safety.

A 2026 review also discusses regenerative and genetic therapies as future directions rather than established standard care.

At present, stem-cell therapy should not be described as an established cure for NOA.

Patients should be especially cautious about expensive commercial treatments promising guaranteed spermatogenesis or biological parenthood.

Gene Therapy and Laboratory-Made Sperm

Research is also exploring:

• Germ-cell generation from stem cells
• Gene correction
• Testicular organoids
• In-vitro spermatogenesis
• Molecular therapies

These developments are scientifically exciting.

But they remain experimental and are not routine fertility treatments for human NOA in 2026.

For current patients, established management remains cause-specific endocrine treatment where applicable and surgical sperm retrieval plus ICSI when focal spermatogenesis exists.

NOA and General Men's Health

NOA should not always be viewed as only a fertility problem.

Recent research has found associations between severe male infertility/NOA and increased long-term risks involving metabolic disease, cardiovascular disease, cancer and mortality.

The EAU also notes these broader health associations in its NOA recommendations.

These are epidemiological associations and do not mean NOA directly causes every such disease.

But they support an important principle:

An infertile man deserves a proper general-health assessment, not merely a semen prescription.

This may include attention to:

• Blood pressure
• Weight
• Glucose
• Lipids
• Testosterone
• Metabolic health
• Testicular examination
• Appropriate cancer-risk follow-up

Non-Obstructive Azoospermia and the Unani System of Medicine

As a physician trained in the Unani System of Medicine, I believe the most useful way to approach severe male infertility is to combine the classical emphasis on individualized, cause-oriented care with modern reproductive diagnostics.

Unani medical literature has historically discussed reduced semen production and male reproductive weakness within concepts such as Qillat-i Mani and Qillat-i Haiwanat-i Manawiya.

CCRUM's standard Unani material discusses Qillat-i Mani/oligospermia and describes individualized principles based upon nutritional state and broader constitutional factors.

However, an important scientific distinction is necessary.

Classical Unani descriptions were developed long before:

• Semen centrifugation
• Micro-TESE
• ICSI
• Chromosomal analysis
• Y-chromosome microdeletion testing
• Modern testicular histology

Therefore, I do not consider it scientifically accurate to say that every classical diagnosis of reduced semen production is equivalent to modern NOA.

Modern diagnosis should come first.

Izala-i-Sabab – Addressing the Cause

One principle of Unani medicine that fits particularly well with modern infertility management is Izala-i-Sabab—identifying and addressing the causative factor.

In NOA this means we should ask:

Is spermatogenesis suppressed because of testosterone injections?

Is the patient hypogonadotropic and therefore medically treatable?

Does he have Klinefelter syndrome?

An AZF deletion?

A history of cryptorchidism?

Previous chemotherapy?

A significant endocrine disorder?

Or irreversible primary spermatogenic failure?

The treatment should follow the mechanism rather than prescribing the same fertility medicine to every man.

Ilaj-bil-Ghiza – Dietotherapy

Unani medicine traditionally gives an important role to Ilaj-bil-Ghiza, or dietotherapy.

CCRUM's description of Unani therapeutic principles includes diet among its core treatment approaches.

In modern NOA care, diet cannot be expected to repair a chromosome or restore completely absent germ cells.

However, appropriate nutrition can support:

• Healthy body weight
• Metabolic health
• General hormonal health
• Adequate micronutrient intake
• Physical energy
• Overall reproductive health

I therefore use dietary advice as part of whole-patient supportive treatment, not as a substitute for genetic diagnosis or micro-TESE when those are needed.

Ilaj-bil-Tadbir – Regimental and Lifestyle Care

Unani regimental care emphasizes regulation of the patient's lifestyle and general physiological state.

In practical contemporary terms, relevant measures can include:

• Regular appropriate activity
• Adequate sleep
• Stress management
• Weight optimization
• Avoidance of tobacco
• Avoidance of anabolic steroids
• Reduction of excessive alcohol
• Metabolic control

These are useful because the reproductive system exists within the health of the entire body.

But I explain to patients clearly:

Improving lifestyle can support reproductive health; it cannot guarantee recovery from severe primary testicular failure.

Ilaj-bil-Dawa – Unani Pharmacotherapy

Unani medicine contains numerous single and compound formulations historically used for male reproductive complaints.

CCRUM publications have reported small or retrospective studies of Unani formulations in oligospermia, with improvements in certain semen parameters in some groups.

These findings can justify further scientific investigation.

But they should not be overstated.

Oligospermia is not the same as non-obstructive azoospermia.

The existing Unani literature does not provide strong modern clinical-trial evidence proving that a particular Unani formulation can restore spermatogenesis in established NOA or reliably produce sperm in men with severe genetic or histological failure.

I therefore regard Unani pharmacotherapy in NOA as individualized supportive care where clinically appropriate, rather than a guaranteed replacement for micro-TESE, genetic evaluation or reproductive technology.

Where Unani Treatment May Be Most Useful

In my view, an integrative Unani approach can be particularly useful in managing modifiable accompanying factors, including:

• Poor nutrition
• Obesity
• Metabolic disease
• Sleep problems
• Chronic stress
• Lifestyle imbalance
• General health issues
• Selected nutritional deficiencies

For a patient with idiopathic severe infertility but some residual testicular function, carefully selected supportive treatment can be considered while objective semen and hormonal monitoring continues.

But if genetic testing demonstrates complete AZFa deletion, herbal medicines cannot reverse that chromosomal deletion.

If histology shows severe germ-cell aplasia, no physician should promise guaranteed regeneration.

The patient's trust is more important than making unrealistic claims.

Ilaj-bil-Yad and Micro-TESE

Unani medicine historically recognizes Ilaj-bil-Yad, procedural or surgical treatment, as one of its therapeutic approaches. CCRUM's official overview specifically describes surgery as part of the Unani therapeutic tradition.

In modern infertility practice, when rare sperm exist only within small areas of the testis, the appropriate procedural intervention is contemporary reproductive microsurgery—particularly micro-TESE.

I therefore do not view referral for micro-TESE as being contrary to an integrative Unani approach.

If a procedure is the most scientifically appropriate way to solve the patient's reproductive problem, recommending it is part of responsible patient care.

The Specialized Saira Health Care Approach to NOA

At Saira Health Care, I believe treatment of NOA should begin with classification rather than a prescription.

A patient should not simply be told:

“You have zero sperm, take medicine for three months.”

We should first determine what type of azoospermia is present and why.

My preferred clinical framework is as follows.

Step 1: Confirm Azoospermia

At least two properly performed semen analyses should confirm absence of sperm after appropriate concentration and microscopic examination.

Rare ejaculated sperm should be actively looked for because finding even a few may change treatment.

Step 2: Distinguish NOA From Obstruction

History, examination, semen characteristics, FSH, LH, testosterone and appropriate imaging are interpreted together.

The management of obstruction and NOA is completely different.

Step 3: Identify Treatable Causes

I look particularly for:

• Hypogonadotropic hypogonadism
• Hyperprolactinemia
• Testosterone or steroid suppression
• Potentially relevant systemic disease
• Selected clinical varicocele
• Reversible toxic or medical exposures

Correcting a genuine reversible cause should come before unnecessary invasive treatment.

Step 4: Perform Appropriate Genetic Evaluation

Karyotype and Y-chromosome microdeletion testing are especially important.

The result may determine whether micro-TESE is reasonable or futile.

Genetic counselling is required when inherited abnormalities are identified.

Step 5: Evaluate the Female Partner Simultaneously

I do not believe the male partner should undergo treatment in isolation for a year while nobody evaluates the woman.

Age and ovarian reserve can completely change the appropriate timing.

For example, months of experimental male treatment may be reasonable in one couple and harmful through lost reproductive time in another.

Step 6: Use Unani Support Where It Has a Rational Role

Diet, lifestyle, sleep, metabolic health and individualized supportive treatment can be addressed.

I monitor objective outcomes rather than assuming that the patient is improving because he “feels stronger.”

Step 7: Refer for Micro-TESE/ICSI When Appropriate

If reversible causes have been addressed, sperm remain absent and the patient is a suitable candidate for biological fertility treatment, micro-TESE and ICSI should be discussed.

This is particularly important when time is becoming a major reproductive factor.

Saira Health Care's Contribution to Sexual Disorders and Infertility

At Saira Health Care, an important part of focused sexual and infertility care is helping patients understand conditions that are commonly confused.

For example:

Azoospermia is not impotence.

Non-obstructive azoospermia is not the same as obstructive azoospermia.

Cryptozoospermia is not absolute azoospermia.

Low semen volume is not automatically low sperm production.

Normal testosterone does not guarantee normal spermatogenesis.

High FSH does not absolutely prove that no focal sperm can exist.

And most importantly:

“No sperm in semen” does not automatically mean “no sperm anywhere in the testes.”

Correct patient education prevents both unnecessary despair and unrealistic promises.

Psychological Impact of NOA

NOA can have a profound effect on emotional health.

A man may experience:

• Shame
• Anxiety
• Guilt
• Depression
• Reduced self-esteem
• Sexual performance anxiety
• Withdrawal from his partner
• Fear of social stigma

WHO's 2025 global infertility guideline recognizes the substantial psychological and social burden of infertility and emphasizes access to psychosocial support.

At Saira Health Care, I consider this part of infertility management rather than an unrelated problem.

A man should not be made to feel that a genetic or testicular disorder defines his masculinity.

Can NOA Cause Erectile Dysfunction?

NOA itself does not automatically cause ED.

However, some underlying disorders can affect testosterone.

And the psychological pressure of infertility can produce performance anxiety and erectile difficulty.

A man who had normal sexual function before his diagnosis may suddenly begin monitoring every erection because he feels that something is “wrong with his masculinity.”

This secondary sexual dysfunction should be recognized and treated separately.

Is Natural Pregnancy Possible With NOA?

If repeated semen analyses confirm complete azoospermia, sperm are not reaching the female reproductive tract.

Natural conception therefore cannot normally occur while true azoospermia persists.

However, if treatment of a reversible endocrine or medication-related cause restores sperm to the ejaculate, natural conception may become possible.

In other men, sperm may only be obtained surgically and used with ICSI.

Can NOA Improve to Cryptozoospermia or Oligozoospermia?

Yes, in selected reversible situations.

Examples include:

• Recovery after stopping anabolic steroids
• Successful treatment of hypogonadotropic hypogonadism
• Correction of certain endocrine problems
• Occasional improvement following treatment of selected modifiable factors

But spontaneous or treatment-related improvement cannot be assumed in severe primary genetic or testicular failure.

Any claimed improvement should be verified with repeat high-quality semen analysis.

Can NOA Be Permanently Cured?

This depends entirely on the cause.

A hormone-deficiency form can sometimes be successfully treated.

Steroid-induced suppression may recover.

Other reversible factors can improve.

But most cases of severe primary testicular spermatogenic failure do not currently have a medicine that reliably restores normal sperm production.

Therefore, instead of promising every patient a permanent cure, I prefer a more useful question:

Can we identify the cause, correct what is reversible, locate sperm if they exist, and choose the best reproductive pathway for this couple?

That is a medically realistic objective.

Frequently Asked Questions About Non-Obstructive Azoospermia

Is NOA the same as zero sperm production?

Not always. Sperm production may be completely absent in some men but focal in others. Small isolated areas of spermatogenesis can sometimes be identified during micro-TESE.

Is NOA worse than obstructive azoospermia?

The biological problem is generally more difficult because sperm production itself is impaired. In obstructive azoospermia, sperm production is often preserved.

Can a man with NOA have normal erections?

Yes. Sperm production and erection are different functions.

Can FSH be normal in NOA?

Yes. Maturation arrest is an important example where FSH can remain normal despite absence of mature sperm.

Does very high FSH mean micro-TESE will definitely fail?

No. High FSH usually indicates severe testicular dysfunction, but it cannot reliably exclude focal areas of sperm production.

What genetic tests are important?

Karyotype analysis and Y-chromosome microdeletion testing are particularly important in confirmed NOA. Further genetic testing can be considered in selected cases.

Can sperm be found with Klinefelter syndrome?

Yes, in selected patients. Published studies report retrieval in a substantial minority, commonly around 40–50%.

Can sperm be found with AZFc deletion?

Sometimes. AZFc has a variable phenotype, and testicular sperm may still be retrievable. Sons conceived from affected sperm inherit the Y deletion.

Can sperm be found with complete AZFa or AZFb deletion?

Current evidence indicates essentially no realistic retrieval probability, and guidelines advise against TESE/micro-TESE in these complete deletions.

Is micro-TESE the preferred surgical procedure?

Yes. Current AUA/ASRM and EAU guidance recommends micro-TESE when surgical sperm retrieval is undertaken for NOA.

What is the average micro-TESE success rate?

Across heterogeneous studies, sperm is found in approximately 40–60% of selected men, but the personal probability varies greatly by cause, genetics and testicular biology.

Does successful micro-TESE guarantee pregnancy?

No. Retrieved sperm must subsequently fertilize an egg through ICSI, embryos must develop, implantation must occur and pregnancy must progress successfully.

Should every NOA patient take hormone injections before micro-TESE?

No. Current evidence does not support routine hormonal stimulation for all NOA patients before surgery. Therapy should be reserved for genuine endocrine indications or carefully selected individualized situations.

Can testosterone injections help?

No. Exogenous testosterone can suppress sperm production and should not be used to treat male infertility.

Should a varicocele always be repaired first?

No. Evidence for routine varicocele repair before sperm retrieval in NOA remains insufficient.

Is stem-cell therapy available as a proven cure?

No. Stem-cell approaches remain experimental and should not currently be presented as an established cure for NOA.

Can Unani medicine help?

Unani medicine can provide an individualized supportive approach through diet, lifestyle, metabolic-health optimization, stress management and carefully selected treatment. CCRUM literature contains preliminary work in oligospermia, but current evidence does not establish a specific Unani formulation as a proven cure for established NOA.

A Message to My Patients

When a patient comes to me and says:

“Doctor, my sperm count is zero. Is everything finished?”

I explain that the word zero on a semen report is the beginning of the investigation—not the end of hope.

First, we need to confirm the diagnosis properly.

Then we need to determine whether the problem is obstruction or sperm production.

If it is non-obstructive, we must ask why.

Could hormones be deficient?

Did testosterone treatment suppress sperm?

Is there a genetic cause?

Were the testes undescended during childhood?

Has chemotherapy damaged spermatogenesis?

Does the patient have Klinefelter syndrome?

Are there focal areas of sperm production that micro-TESE may identify?

These questions matter.

I also tell patients:

Do not compare yourself with another azoospermia patient.

One man's condition can be completely different from another's despite both semen reports saying “no sperm.”

That is why individualized treatment is essential.

About Dr. Nizamuddin Qasmi

Dr. Nizamuddin Qasmi
Founder & Chief Physician, Saira Health Care
Focused Practice in Sexual Disorders & Infertility

Professional Qualifications and Training

BUMS – Hamdard University, Delhi
MD
CGO
Certificate in Infertility – MGBIMS, Delhi
Certificate in Urology – London, UK
Masters in Male Infertility – MasterHealthPro (HealthPro)
Integrated Sexual and Reproductive Health – ISRH, UNFPA

At Saira Health Care, Dr. Nizamuddin Qasmi's focused clinical approach includes sexual disorders, male and female infertility, severe male-factor infertility, ejaculatory disorders, reproductive counselling and individualized Unani supportive care.

In a complex condition such as NOA, the clinical objective is not simply to prescribe a “sperm medicine.” It is to establish the type and cause of azoospermia, recognize reversible conditions, arrange appropriate genetic and hormonal investigation, protect the couple's reproductive time and coordinate referral for micro-TESE/ICSI or genetic counselling where necessary.

Conclusion

Non-Obstructive Azoospermia is one of the most severe forms of male infertility, but it is not one single disease and it does not have one single prognosis.

It occurs when sperm are absent from ejaculated semen because spermatogenesis is severely impaired rather than because of a reproductive-tract blockage.

Its causes include:

• Chromosomal abnormalities
• Y-chromosome microdeletions
• Klinefelter syndrome
• Cryptorchidism
• Testicular injury
• Mumps orchitis
• Cancer treatment
• Testosterone or anabolic-steroid suppression
• Hormonal disorders
• Idiopathic spermatogenic failure

Correct diagnosis begins with confirming azoospermia on properly processed repeat semen analyses and distinguishing NOA from obstructive azoospermia. Current guidelines recommend comprehensive evaluation with history, examination, reproductive hormones, genetic testing and appropriate imaging.

Genetic evaluation is especially important. Karyotyping and Y-chromosome microdeletion testing can identify the cause, guide counselling and sometimes prevent futile surgery. Complete AZFa and AZFb deletions have essentially no meaningful sperm-retrieval potential, whereas AZFc deletion and Klinefelter syndrome may still permit sperm retrieval in a significant proportion of appropriately selected patients.

Treatment must be cause-specific.

Hypogonadotropic hypogonadism can often be treated medically with gonadotropin therapy. Exogenous testosterone should be avoided when fertility is desired. Routine hormonal stimulation before micro-TESE in primary testicular NOA remains unsupported by strong evidence.

For men who remain azoospermic but may have focal spermatogenesis, micro-TESE followed by ICSI represents the main established pathway toward biological fatherhood. Published sperm-retrieval rates commonly fall around 40–60%, but individual outcomes remain difficult to predict.

The latest research in 2025–2026 is increasingly focused on precision genetics, predictive models, molecular biomarkers, artificial intelligence and phenotype-guided endocrine treatment, but these developments have not yet replaced conventional clinical assessment and micro-TESE.

From the Unani perspective, the traditional emphasis on identifying causative factors, individualized diet, lifestyle regulation and whole-patient health can contribute meaningfully to supportive care. CCRUM literature also contains preliminary studies in oligospermia.

However, responsible integrative medicine requires recognizing that NOA is not equivalent to ordinary low sperm count, and no Unani medicine has currently been proven in high-quality clinical trials to reverse severe genetic or histological spermatogenic failure.

At Saira Health Care, my approach is therefore to combine the strengths of individualized Unani care with modern male-infertility diagnostics and reproductive medicine.

The objective is to:

identify what can be treated, avoid what can cause further harm, locate sperm when biologically possible, provide honest genetic and reproductive counselling, and help each couple choose the most appropriate path toward parenthood.

Most importantly, I want patients with NOA to understand:

A zero-sperm semen report does not measure masculinity, and it does not automatically prove that every part of the testis contains zero sperm. Proper investigation is the foundation of the next decision.

For more information:
https://www.sairahealthcare.com/

Book an appointment:
https://www.sairahealthcare.com/Appointment.aspx

Saira Health Care Pharmacy:
https://pharmacy.sairahealthcare.com/

Medical Disclaimer: This article is intended for general medical education and patient awareness. Non-obstructive azoospermia requires individualized evaluation by appropriately qualified infertility, andrology/urology and reproductive-medicine professionals. Genetic abnormalities can have implications for patients and future children and should receive appropriate genetic counselling. Testosterone, fertility hormones, herbal medicines, Unani formulations, supplements and experimental therapies should not be started solely on the basis of online information. Micro-TESE does not guarantee sperm retrieval, and successful sperm retrieval does not guarantee fertilization, pregnancy or live birth.